Genomic Health Receives Average Recommendation of “Hold” from Analysts (NASDAQ:GHDX)
Genomic Health (NASDAQ:GHDX) has received a consensus rating of “Hold” from the ten brokerages that are covering the stock, American Banking and Market News reports. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $27.50.
Separately, analysts at Canaccord Genuity reiterated a “hold” rating on shares of Genomic Health in a research note on Monday, August 11th. They now have a $27.00 price target on the stock, down previously from $30.00.
Genomic Health (NASDAQ:GHDX) opened at 29.12 on Monday. Genomic Health has a one year low of $23.90 and a one year high of $37.24. The stock has a 50-day moving average of $27.08 and a 200-day moving average of $27.03. The company’s market cap is $918.1 million.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.26) by $0.11. The company had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.04 million. During the same quarter in the prior year, the company posted ($0.10) earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.80 earnings per share for the current fiscal year.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.